Table 3.
Primary and secondary outcomes following treatment of in-stent restenosis
| Drug-eluting balloon (n = 91) | Drug-eluting stent (n = 89) | Adjusted hazards ratio* (95% confidence interval) |
p-value | |
|---|---|---|---|---|
| MACE | 36% | 19% | 1.45 (0.75-2.83) | 0.27 |
| All-cause death | 23% | 7% | 2.85 (0.98-8.32) | 0.06 |
| Non-fatal myocardial infarction | 9% | 6% | 1.40 (0.43-4.6) | 0.58 |
| Target-lesion revascularization | 10% | 8% | 1.29 (0.44-3.76) | 0.64 |
| Binary restenosis | 13% | 9% | 1.03 (0.37-2.88) | 0.95 |
| Lesion thrombosis | 1% | 0% | 78.96 (N/A) | 0.67 |
| All-cause revascularization | 24% | 16% | 1.23 (0.57-2.63) | 0.60 |
MACE: major adverse cardiovascular events.
*
Adjusted Cox proportional hazards model, including age, body mass index, diabetes, chronic renal disease, and acute coronary syndrome as the indication for revascularization.